Patent classifications
A61K47/6925
Nanoparticle-stabilized nanocapsules and methods of preparation and use for nucleic acid delivery
The invention provides nanoparticle-stabilized nanocapsules, and methods of their preparation and use in delivery of therapeutics, such as nucleic acids. Various embodiments disclosed relate to a nanoparticle-stabilized nanocapsule. Various embodiments disclosed relate to nanoparticle-stabilized nanocapsules for nucleic acid delivery into cells. Various embodiments provide methods of using the nanocapsule for in vivo delivery of the nucleic acid materials.
METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY
The present application provides methods of treating a colon cancer (such as advanced and/or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody (such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6).
Polymer systems and their applications in diagnostics and drug delivery
The present invention provides a biodegradable precision polymer system (poly system) and methods for preparing pharmaceutically effective precision polymer nanosystems (polymer nanosystem) for delivery and/or targeting of drugs or drug like compounds.
Targeted shell for use in drug delivery system utilizing carbosilane dendrimer
The present invention is related to a targeted type shell for drug delivery system. The object of the present invention is to provide the targeted type shell for DDS, which comprises a carbosilane dendrimer containing a silole produced by which is formed by utilizing the reaction between thiol group and alkyl halide, and a targeted protein containing a labeled proteins such as green fluorescent protein with a target recognition site. The shell may incorporate compounds having a variety of molecular weight and biopolymers, and selectively deliver them into targeted cells.
SYSTEM FOR DELIVERY OF MEDICAL COMPONENTS TO THE LUNGS
The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.
Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody
Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
NANOBUBBLES
The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.
METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
SYNTHETIC BINDER OF BREAST CANCER STEM CELLS
The present disclosure provides a for peptoid compounds that bind selective to cancer stem cells (CSCs), particularly those associated with breast cancer. Conjugates of the peptoids to detactable labels and therapeutic agent are contemplated as are methods of diagnosing and treating breast cancer.
METAL BISPHOSPHONATE NANOPARTICLES FOR ANTI-CANCER THERAPY AND IMAGING AND FOR TREATING BONE DISORDERS
Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.